替尔泊肽新适应证在华获批

Core Viewpoint - Eli Lilly announced that Mounjaro (tirzepatide injection) has received approval from the National Medical Products Administration (NMPA) in China, becoming the first and currently the only prescription medication for treating moderate to severe obstructive sleep apnea (OSA) in adult patients with obesity [1] Group 1 - Tirzepatide can improve sleep disorders in adult patients with moderate to severe obstructive sleep apnea and obesity [1] - The use of this indication requires a foundation of dietary control and increased physical activity [1]